alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Antitrust Division

                    Notice is hereby given that, on October 11, 2023, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301*et seq.*                     (“the Act”), the Integrated Photonics Institute for                           ( print page 86939)                        Manufacturing Innovation operating under the name of the American Institute for Manufacturing Integrated Photonics (“AIM Photonics”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.                

Specifically, Georgia Tech Applied Research Corporation, Atlanta, GA; and Northrop Grumman Systems Corporation, Falls Church, VA, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and AIM Photonics intends to file additional written notifications disclosing all changes in membership.

                    On June 16, 2016, AIM Photonics filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the                     **Federal Register**                     pursuant to section 6(b) of the Act on July 25, 2016 (81 FR 48450).                

                    The last notification was filed with the Department on August 1, 2023. A notice was published in the                     **Federal Register**                     pursuant to section 6(b) of the Act on October 6, 2023 (88 FR 69671).                

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2023-27564 Filed 12-14-23; 8:45 am]

BILLING CODE 4410-11-P
December 17, 2001

CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 01-16

Subject: Autogenous Products for Avian Influenza

To: Biologics Licensees, Permittees, and Applicants

Directors, Center for Veterinary Biologics

Veterinary Services Management Team

Area Veterinarians in Charge, VS

State Veterinarians

The purpose of this notice is to remind interested parties that domestic distribution and use of

avian influenza (AI) vaccines for any species may only be done under the supervision and

control of USDA, APHIS, Veterinary Services (VS). 

Requirements for the licensure of AI vaccines and a summary of the restrictions on their use are

provided in Veterinary Services Memorandum No. 800.85, dated July 23, 1999. Avian

influenza is considered a program disease by APHIS, VS, and any importation or interstate

movement of AI viruses is strictly regulated and is only authorized by permit in accordance with

9 CFR 122.2. 

The practice of producing AI vaccines as autogenous products under a firm's existing

autogenous product license without specific authorization from APHIS, VS, does not meet

these requirements and is prohibited. The Center for Veterinary Biologics (CVB) will not

release autogenous AI vaccines without authorization from both the relevant State authorities,

responsible officials of APHIS, VS, and if necessary, required permits for interstate transport.

/s/ Steven A. Karli

Steven A. Karli

Director

Center for Veterinary Biologics

 APHIS - Protecting American Agriculture

 An Equal Opportunity Employer

United States

Department of

Agriculture

Marketing and

Regulatory

Programs

Animal and Plant

Health Inspection

Service

Veterinary Services

Center for Veterinary

Biologics

Suite 104

510 South 17th Street

Ames, IA 50010

(515) 232-5785

FAX (515) 232-7120
### Delaware Aviation Museum Foundation 21781 Aviation Avenue Georgetown, Delaware 1994 7 Phone:302

-854

-0244 January 11, 2015 VIA ELECTRONIC SUBMISSION Federal Aviation Administration c/o U.S. Department ofTransportation Docket Management System 800 Independence Avenue Washington, D.C. 20591-0004
To Whom It May Concern: The Delaware Aviation Museum Foundation, a 501(c)(3) organization based at the Sussex County Airport, Georgetown, Delaware, is the holder of Exemption 8702D and Exemption 10872. The mailing address on both ofthese exemptions is 21513 Rudder Lane, Georgetown, De 19947. Due to new street construction at the Sussex County Airport, and reassignment of addresses at the airport to conform to Emergency Management requests, our new mailing address is: 21781 Aviation Avenue, Georgetown Delaware, 1994 7
. Our physical location has not changed, just the mailing address as assigned by Emergency Management and the U
.S. Postal Service. I am requesting the mailing address of record for both of the above referenced FAA Exemptions, be changed to 21781 Aviation Avenue, Georgetown Delaware 19947.

Larry D. Kelley VP and Executive Director Delaware Aviation Museum Foundation

1
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1000
<CURRENCY> US DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          JUN-30-1997
<PERIOD-START>                             JUL-01-1996
<PERIOD-END>                               MAR-31-1997
<EXCHANGE-RATE>                                      1
<CASH>                                          23,204
<SECURITIES>                                    41,998
<RECEIVABLES>                                   24,250
<ALLOWANCES>                                       561
<INVENTORY>                                      3,075
<CURRENT-ASSETS>                               100,364
<PP&E>                                          15,200
<DEPRECIATION>                                   4,175
<TOTAL-ASSETS>                                 166,488
<CURRENT-LIABILITIES>                           34,360
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           132
<OTHER-SE>                                      62,242
<TOTAL-LIABILITY-AND-EQUITY>                   166,488
<SALES>                                         71,268
<TOTAL-REVENUES>                                71,268
<CGS>                                           39,249
<TOTAL-COSTS>                                   66,873
<OTHER-EXPENSES>                                    12
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               2,293
<INCOME-PRETAX>                                  4,243
<INCOME-TAX>                                     1,502
<INCOME-CONTINUING>                              2,729
<DISCONTINUED>                                  (9,914)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (7,185)
<EPS-PRIMARY>                                   (0.54)
<EPS-DILUTED>                                   (0.54)
        

</TABLE>
CSB BANCORP, INC.EXHIBIT 32.1SECTION 1350 CERTIFICATIONIn connection with the quarterly report of CSB Bancorp, Inc. (the “Company”) on Form 10-Q for thethree-month period ended March 31, 2006 as filed with the Securities and Exchange Commission on thedate hereof (the “Report”), I, Eddie L. Steiner, President and Chief Executive Officer, certify,pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of2002, that to the best of my knowledge: (1) The Report fully complies with the requirements of section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and  (2) The information contained in the Report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.   /s/ Eddie L. Steiner     Eddie L. Steiner  President and  Chief Executive Officer   * This certification is being furnished as required by Rule 13a-14(b) under the Securities ExchangeAct of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United StatesCode, and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwisesubject to the liability of that section. This certification shall not be deemed to be incorporatedby reference into any filing under the Securities Act of 1933 or the Exchange Act, except asotherwise stated in such filing.
23.
# C_2020061EN.01002702.xml

| 24.2.2020 | EN | Official Journal of the European Union | C 61/27 |
| --- | --- | --- | --- |

24.2.2020

EN

Official Journal of the European Union

C 61/27

---

Judgment of the General Court of 19 December 2019 — Czech Republic v Commission

(Case T-509/18) (1)

(EAGF and EAFRD - Expenditure excluded from financing - Applicable time periods between multiple visits by the national control authorities - Announcement of on-the-spot checks - Implied notice - Articles 25 and 26 of Implementing Regulation (EU) No 809/2014 - Flat rate financial correction)

(2020/C 61/33)

Language of the case: Czech

Parties

Applicant: Czech Republic (represented by: M. Smolek, J. Pavliš, O. Serdula and J. Vláčil, acting as Agents)

Defendant: European Commission (represented by: A. Lewis, A. Sauka and K. Walkerová, acting as Agents)

Re:

Application under Article 263 TFEU seeking annulment of Commission Implementing Decision (EU) 2018/873 of 13 June 2018 excluding from European Union financing certain expenditure incurred by the Member States under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD) (OJ 2018 L 152, p. 29) in so far as it excludes expenditure of a total of EUR 151 116,65 incurred by the Czech Republic under the EAFRD.

Operative part of the judgment

The Court:

| 1. | Annuls Commission Implementing Decision (EU) 2018/873 of 13 June 2018 excluding from European Union financing certain expenditure incurred by the Member States under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD) in so far as the European Commission excluded under that decision expenditure of a total of EUR 151 116,65 incurred by the Czech Republic under the EAFRD; |
| --- | --- |

1.

Annuls Commission Implementing Decision (EU) 2018/873 of 13 June 2018 excluding from European Union financing certain expenditure incurred by the Member States under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD) in so far as the European Commission excluded under that decision expenditure of a total of EUR 151 116,65 incurred by the Czech Republic under the EAFRD;

| 2. | Orders the Commission to pay the costs. |
| --- | --- |

2.

Orders the Commission to pay the costs.

---

(1)  OJ C 399, 5.11.2018.

---
# **Exhibit 32**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER ANDCHIEF FINANCIAL OFFICER**

 

Pursuant to 18 U.S.C. § 1350 and in connection with theaccompanying report on Form 10-Q for the period ended June 30, 2005 thatis being filed concurrently with the Securities and Exchange Commission on thedate hereof (the “Report”), each of the undersigned officers of ClaytonWilliams Energy, Inc. (the “Company”), hereby certifies that:

 

1.               TheReport fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and

 

2.               Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 

 
|   | /s/ Clayton W. Williams |
|--------|-------------------------|
|   | Clayton W. Williams     |
|   | Chief Executive Officer |
|   | August 9, 2005     |
|   |                    |
|   |                    |
|   | /s/ Mel G. Riggs        |
|   | Mel G. Riggs            |
|   | Chief Financial Officer |
|   | August 9, 2005     |

 

----
# C_2019399EN.01005101.xml

| 25.11.2019 | EN | Official Journal of the European Union | C 399/51 |
| --- | --- | --- | --- |

25.11.2019

EN

Official Journal of the European Union

C 399/51

---

Judgment of the General Court of 17 September 2019 — Grupo Bimbo v EUIPO — Rubio Snacks (Tia Rosa)

(Case T-464/18) (1)

(EU trade mark - Opposition proceedings - Application for EU figurative mark Tia Rosa - Earlier national figurative mark TIA ROSA - Relative ground for refusal - Similarity of the goods - Article 8(1)(b) of Regulation (EU) 2017/1001)

(2019/C 399/61)

Language of the case: Spanish

Parties

Applicant: Grupo Bimbo, SAB de CV (Mexico, Mexico) (represented by: N. Fernández Fernández-Pacheco, lawyer)

Defendant: European Union Intellectual Property Office (represented by: J. Crespo Carrillo and H. O’Neill, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Rubio Snacks, SL (Bullas, Spain) (represented by I. Temiño Ceniceros and J. Oria Sousa-Montes, lawyers)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 18 May 2018 (Case R 2739/2017-5), relating to opposition proceeding between Rubio Snacks and Grupo Bimbo.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Grupo Bimbo, SAB de CV to pay the costs. |
| --- | --- |

2.

Orders Grupo Bimbo, SAB de CV to pay the costs.

---

(1)  OJ C 328, 17.9.2018.

---
COURT OF APPEALS

SECOND DISTRICT OF TEXAS

FORT WORTH

NO. 02-12-00103-CV

$5,990.00 IN U.S. CURRENCY; 

AND 1999 MERCURY

APPELLANTS

V.

THE STATE OF TEXAS APPELLEE

----------

FROM THE 372ND DISTRICT COURT OF TARRANT COUNTY

----------

MEMORANDUM OPINION1

----------

Bobby Glen Turner, Jr. attempts to appeal from an “Interlocutory Nihil Dicit 

Judgment” that was signed on February 27, 2012. On March 16, 2012, we

informed the parties of our concern that we might not have jurisdiction over this 

appeal because the “Interlocutory Nihil Dicit Judgment” did not appear to be a 

final judgment or an appealable interlocutory order and that the appeal could be 

 

1See Tex. R. App. P. 47.4.
2

dismissed for want of jurisdiction unless any party desiring to continue the appeal 

filed a response on or before March 26, 2012, showing grounds for continuing 

the appeal. We received no response. Because the “Interlocutory Nihil Dicit 

Judgment” signed by the trial court on February 27, 2012, does not constitute an 

appealable interlocutory order, we dismiss the appeal for want of jurisdiction.

See Tex. R. App. P. 42.3(a), 43.2(f); Tex. Civ. Prac. & Rem. Code Ann. § 51.014 

(West Supp. 2008) (setting forth appealable interlocutory orders). But see Fid. & 

Cas. Co. of NY v. Vogel, No. B14-88-00005-CV, 1988 WL 83827, at *1 (Tex. 

App.—Houston [14th Dist.] Aug. 11, 1988, writ denied) (reaching merits of appeal 

from an interlocutory nihil dicit judgment because trial court had granted a motion 

for severance of the judgment on the cross-action, enabling Fidelity to pursue its 

appeal).

PER CURIAM

PANEL: WALKER, MCCOY, and MEIER, JJ.

DELIVERED: May 3, 2012
Navigate to Homepage
Search
Main navigation
  

        
              Explore the Capitol Campus
                          Art
                            Buildings & Grounds
                            Capitol Hill Facts
                            Visitor Resources
                            Our Blog
                            What We Do
                          Areas of Expertise
                            Programs & Ceremonies
                            Projects
                            Publications
                            Strategic Objectives
                            About Us
                          Who We Are
                            History of the AOC
                            News & Notices
                            Organizational Structure
                            Partnerships & Recognition
                            Work With UsSearch Your Message Has Been Received
Thank you for your interest, your message successfully has been received. Serve. Preserve. Inspire.

              Contact Us
                            Accountability
                            Hill Staff Resources
                            AOC Staff Resources
Utility
  

        
              Privacy Policy
                            Image Terms of Use
                            Inspector General
                            U.S. Botanic Garden
                            U.S. Capitol Visitor CenterFacebook
	Twitter
	Flickr
	YouTube
	Instagram
	Subscribe
Exhibit 31.2

                                 CERTIFICATIONS

I, Dean L. Cash, certify that:

1.  I  have  reviewed  this  quarterly  report  on  Form  10-QSB  of  ATEL  Cash
Distribution Fund IV, LP;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact  necessary to make the statements
made, in light of the  circumstances  under which such statements were made, not
misleading with respect to the period covered by this report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information included in this report, fairly present in all material respects the
financial  condition,  results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4.  The  registrant's  other  certifying  officer  and  I  are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

     a)  designed  such  disclosure  controls  and  procedures,  or caused  such
     disclosure controls and procedures to be designed under our supervision, to
     ensure that material  information  relating to the registrant is made known
     to us by others within the entity,  particularly during the period in which
     this report is being prepared;

     b) evaluated the effectiveness of the registrant's  disclosure controls and
     procedures  and  presented  in  this  report  our  conclusions   about  the
     effectiveness of the disclosure  controls and procedures,  as of the end of
     the period covered by this report based on such evaluation; and

     c) disclosed in this report any change in the registrant's internal control
     over financial  reporting that occurred during the registrant's most recent
     fiscal  quarter that has  materially  affected or is  reasonably  likely to
     materially   affect  the  registrant's   internal  control  over  financial
     reporting; and

5. The registrant's other certifying officer and I have disclosed,  based on our
most recent  evaluation of internal  control over  financial  reporting,  to the
registrant's  auditors  and the audit  committee  of the  registrant's  board of
directors (or persons performing the equivalent functions):

     a) all significant  deficiencies  and material  weaknesses in the design or
     operation of internal control over financial reporting which are reasonably
     likely to adversely  affect the  registrant's  ability to record,  process,
     summarize and report financial information; and

     b) any fraud,  whether or not material,  that involves  management or other
     employees who have a significant role in the registrant's internal controls
     over financial reporting.

Date:          November 11, 2004


/s/ Dean L. Cash
-------------------
Dean L. Cash
President and Chief Executive
Officer of General Partner
Exhibit 32.2



CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002



Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer
of Checkers Drive-In Restaurants, Inc. (the Company), does hereby certify, to such officers knowledge, that the Quarterly Report on Form 10-Q for the quarter ended June 20, 2005 of the Company fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.



|                       
|-----------------------
|/s/ S. Patric Plumley  
|S. Patric Plumley      
|Chief Financial Officer
|August 1, 2005         



A signed original of this written
statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



24
August 27, 1999

21952

#### State v. Akina

Affirmed
Title: Adjuvants and Excipients

Release Date: 26 Feb 2020 Author: Document Number: CVB-SOP-0078.02

CONTROLLED//PROPIN//BASIC

Printed by: CRRYAN on 26 Feb 2020, 09:49:44 am.

Controlled by: APHIS Center for Veterinary Biologics, 515-337-6100




Title: Adjuvants and Excipients

Release Date: 26 Feb 2020 Author: Document Number: CVB-SOP-0078.02

CONTROLLED//PROPIN//BASIC

Printed by: CRRYAN on 26 Feb 2020, 09:49:44 am.

Controlled by: APHIS Center for Veterinary Biologics, 515-337-6100